A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

← catalyst calendar

NCT07545122 · readout ≤ 1,261 d

Sponsored by Context Therapeutics Inc. (industry) · CNTX — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

162estimated

Sites

Country

Australia

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Sep 2026

estimated

When the study began enrolling

Primary completion

Jan 2030

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2030

estimated

The whole study's end, after follow-up

First posted

2026-04-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Triple Negative Breast Cancer (TNBC)
Colorectal Cancer
Urothelial Cancer

Intervention

Drug: CT-202

Primary outcomes

what the primary-completion date above is the date OF

Phase 1a: Incidence of Dose Limiting Toxicities (DLTs)

measured From date of first dose of CT-202 until 28 days following the first dose

Phase 1b: Overall response rate (ORR)

measured From date of first dose of CT-202until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Permalink · CNTX's whole pipeline · Catalyst calendar · Every registered study · What changed